Lucid Diagnostics Inc (LUCD) Stock Price, Quote & News

Company Profile

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths t...

Industry: Medical Devices

Sector: Healthcare

Phone: 917 813 1828

Website: www.luciddx.com

Address:

360 Madison Avenue, 25th Floor, New York, United States

chuckjackson May. 31 at 4:17 PM

$PAVM $LUCD part of the reason I brought up the topic of whether draft LCDs occur in June is that I wanted to adjust my expectations on when to expect the draft. There were weeks when I have been very disappointed that the draft has not been received since my expectations were so high. With management now communicating "near future" instead of imminent, I have become uncertain on what to expect. We are at the 9 months point post-cac. Any sense of timeliness given a very positive meeting is also fading. Given what I've seen, my expectations are going to take a summer vacation. Imo, the next chance for a draft will be mid-July. I will still check each week for the 1% chance as my holdings are in pavm, and I believe that any spike will be short lived given the participation of Ayrton, the 4.61M shares of call-able warrants and the dillutive structure in place.

1 · Reply

oaksapollo May. 31 at 3:44 PM

$LUCD What I find most interesting about the article below is that it seems to be written by a NJ internal medicine doc with no conflict of interest of any kind. Not a gastroenterologist, not a KOL, not a pathologist. This is a very, very good sign. The backbone of the medical establishment is now aware of Esoguard and excited about the potential. Now...if we could just get coverage.

0 · Reply

oaksapollo May. 31 at 4:33 AM

$LUCD Very nicely written article: https://www.sciencedirect.com/science/article/pii/S2772572326001500 The one thing I'll add is that those "7 unnecessary EGDs" are patients that per AGA guidelines, were supposed to get an EGD anyway. I feel like the author spun it negatively when really it's a non-issue. Say you have 100 people who meet the screening criteria: No Esoguard: all 100 get an EGD + Esoguard: 90 are negative and need no further testing, 10 get EGD Obviously the + Esoguard situation is better. And also, we know that with no Esoguard, 100 aren't getting the EGD, only 10 are. So the number of EGDs actually stays the same in either scenario, but the GIs are now scoping 10 patients to find 3 cases of dysplasia instead of screening 10 and probably finding nothing (since those 3 positive patients are randomly scattered amongst the whole population of 100). In other words it "increases the yield" of endoscopy. The readers of Gastro Hep Advances are really in for a treat.

0 · Reply

chuckjackson May. 30 at 2:22 PM

$LUCD $PAVM @oaksapollo have you seen anything to indicate that June historically is a slow month (possibly because of vacations) and we will need to wait for July / August? According to Gemini, this is the draft lcd activity for summer 2025.

3 · Reply

dmc4321 May. 30 at 8:41 AM

$LUCD No it is not a contract. It is a license to hunt. There are no sales volumes or dollars. All it does is after LUCD has contacted each individual VA facility and SOLD to that individual facility the EsoGuard test and that individual VA facility has scheduled and performed an EsoGuard test does it become relevant. If you knew ANYTHING you would know that after CMS approval it normally takes a DECADE before adoption is widespread. How do you get there when currently after a year of INTENSE FOCUS the current sales force has FAILED AGAIN to increase the number of covered tests done in a Quarter. If you knew ANYTHING you would know that most test fail, not because they cant get CMS approval but that they cant be sold in sufficient volumes. Thats LUCD's problem today. They are stuck at 500 tests a quarter utilizing their 29 salesreps. Getting to break even is 3 years at BEST which if you are losing $50M+ a year is another 200M shares MASSIVE DILUTION AHEAD.

0 · Reply

oaksapollo May. 29 at 2:03 PM

$LUCD Another possibility on the Esophageal Cancer Awareness Act is that Trump does nothing for 10 days and it automatically becomes law. That would be a bit sad but we are almost there.

1 · Reply

SaroCali May. 29 at 1:29 PM

$LUCD Just some basic numbers that keep me in this stock: The VA contract has 9 million potential patients. Of those patients, approximately 70% are over 50, nearly all of them are male, and most are white. Let's bring it down to 60% of the total number of potential VA healthcare members are potential users of Esocheck/Esoguard. That means that if only 1% of the total patient pool actually take the test each year, LUCD would have 9,000,000x0.6x0.01 = 54,000 tests. 54,000 tests at $1,900 of revenue per test equals $102M in annual revenue. At a 5x multiplier, the market cap would be $500M. That's 2.5 times the current share price. Say there's some more dilution down the road, it'll still double if only 1% of the patient pool actually takes the test. That's not considering Medicare, the private payer networks, or other revenue streams (which are 10x bigger in aggregate than the VA). With all that said, I give a $3B to $5B market cap estimate within 2 years. That's $15-25/share.

1 · Reply

crypto_biotech May. 29 at 8:36 AM

$LUCD Nothing new. I use AI to check as part of a series of tasks every day. When I wake up I know. If you are not using AI to invest you are behind the curve.

1 · Reply

dmc4321 May. 29 at 12:12 AM

$LUCD & $PAVM @RetiredMD @oaksapollo @PortfolioMgmt23 are all competing for the biggest WHOPPER of the week. They all tried hard but I have got to say that @RetiredMD wins it be a NOSE (🤥 🤥) If you had any brains this would scare you straight. The commercial success of EsOguard has always been about PCP's both ordering and as importantly DOING THE TESTS on site. Look at these ColoGuard stats from 2014 and compare to LUCD's 2000 tests a year which is the current run rate. During 2014, Exact Sciences generated an estimated roughly $1.5 million from Cologuard, the company said on January 12, citing preliminary data. Exact Sciences said it completed and reported diagnostic results for 4,024 Cologuard tests, while more than 4,000 physicians wrote at least one prescription for the test. The patient compliance rate was 74.6% as of December 31. In 2014 they had 4000 PCP's writing scripts. Today EsoGuard has MAYBE 200 PCP's writing scrips. Thats what you need to SCALE. PCP's.

1 · Reply

tds_ May. 28 at 6:09 PM

$LUCD A bit above my paygrade, but I see that ANGO (Angio Dynamics) announced today that Palmetto GBA issued a final LCD for their nanoknife IRE in prostate, liver cancer. Timeline according to google gemini: March 10, 2025: An initial open meeting took place concerning this coverage policy, though no oral presentations were formally registered at that time. August 25, 2025: A specialized MolDX Open Meeting addressed genetic testing policies and also allowed for the submission of written and oral comments regarding related cancer treatments. October 27, 2025: A Jurisdictions J and M Open Meeting was held where the NanoKnife procedure for soft tissue/prostate cancer ablation was a primary topic for oral presentations.

2 · Reply

Lucid Diagnostics price target lowered to $2 from $3 at Maxim

May 15, 2026, 8:00 AM EDT - 16 days ago

Market Cap	209.16M
Revenue (ttm)	4.71M
Net Income (ttm)	-58.01M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,231.63%
Debt to Equity Ratio	6.30

Volume	772,300
Avg Vol	854,752
Day's Range	N/A - N/A
Shares Out	203.07M
Stochastic %K	59%
Beta	1.10
Analysts	Strong Sell
Price Target	$3.90